Other Events ·
At its 2026 Annual Meeting of Stockholders on June 18, 2026, EyePoint, Inc. stockholders approved an amendment to the…
EYPTEyePoint, Inc.
At its 2026 Annual Meeting of Stockholders on June 18, 2026, EyePoint, Inc. stockholders approved an amendment to the 2023 Long-Term Incentive Plan, increasing the number of authorized common shares for issuance by 4,900,000. Stockholders also elected eight directors, ratified the appointment of Deloitte & Touche LLP as the independent auditor for fiscal year 2026, and approved named executive officer compensation on a non-binding advisory basis. The company operates in the biotechnology industry and develops ophthalmic pharmaceuticals.